New 1,3,4‒oxadiazole Quinazolines as Potential Anticancer Agents: Design, Synthesis, Biological Evaluation, and In silico Studies. 2024

Venkanna Gujja, and Kumaraswamy Sadineni, and Shiva Kumar Koppula, and Avanthi Basireddy, and Banothu Venkanna, and Shravan Kumar Gunda
Department of Chemistry, Gitam deemed to be University, Hyderabad campus, Rudraram, Sangareddy, Hyderabad, 502329, Telangana, India.

BACKGROUND A novel series of 1,3,4‒oxadiazole connected to derivatives of quinazolinone (7a-e and 8a-f) was synthesized in the current investigation, and its anticancer and Topoisomerase‒ II inhibitory activity was evaluated. OBJECTIVE These findings inspired the design, synthesis, and biological analysis of these 1,3,4‒oxadiazole-quinazolinone analogues as antiproliferative Topo‒II inhibitors. METHODS The novel compound structures were determined using mass spectrometry and spectral methods (IR, NMR: 1H & 13C). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide colourimetric assay has been used to evaluate the anticancer efficacy of these drugs, and Autodock 4.2 provides a description of the docking results. For the more active members, additional biological tests, such as the Topo‒II inhibition experiment, were performed. These compounds' physicochemical and ADMET characteristics were examined in more detail. RESULTS In the experiment for antiproliferative activity, compounds 7d, 7e, 8c, 8e, and 8f demonstrated encouraging cytotoxicity findings against HCT‒116 and HepG2 cancer cell lines, with IC50 values ranging from 3.85 to 19.43 μM. Compounds 7d, 7e, and 8e were the most potent inhibitors of Topo II with IC50 values of 15.18, 17.55, and 12.59 μM, respectively. Additionally, the docked compound 8c showed the strongest conventional hydrogen bonds among the residues Leu507(B), Asn508(B), Asn520(B), and Glu522(B) in the Human topoisomerase‒IIβ active site in the DNA complex (4G0U) when compared to the findings of docking experiments. CONCLUSIONS New findings have discovered the fact that fused 1,3,4‒oxadiazole bearing quinazolinone contributed great significance in the field of medicinal chemistry due to their diverse biological properties. Finally, the in silico pharmacokinetic profile of all the synthesized derivatives was estimated using SwissADME, where some of the compounds followed Lipinski, Veber, Egan, and Muegge rules without deviation. The result of this activity advises that with a simple modification in structure, a potent anticancer agent can be generated with good efficacy.

UI MeSH Term Description Entries

Related Publications

Venkanna Gujja, and Kumaraswamy Sadineni, and Shiva Kumar Koppula, and Avanthi Basireddy, and Banothu Venkanna, and Shravan Kumar Gunda
January 2022, Bioorganic & medicinal chemistry,
Venkanna Gujja, and Kumaraswamy Sadineni, and Shiva Kumar Koppula, and Avanthi Basireddy, and Banothu Venkanna, and Shravan Kumar Gunda
June 2021, Bioorganic chemistry,
Venkanna Gujja, and Kumaraswamy Sadineni, and Shiva Kumar Koppula, and Avanthi Basireddy, and Banothu Venkanna, and Shravan Kumar Gunda
November 2011, Bioorganic & medicinal chemistry,
Venkanna Gujja, and Kumaraswamy Sadineni, and Shiva Kumar Koppula, and Avanthi Basireddy, and Banothu Venkanna, and Shravan Kumar Gunda
May 2012, Bioorganic & medicinal chemistry,
Venkanna Gujja, and Kumaraswamy Sadineni, and Shiva Kumar Koppula, and Avanthi Basireddy, and Banothu Venkanna, and Shravan Kumar Gunda
March 2023, Journal of biomolecular structure & dynamics,
Venkanna Gujja, and Kumaraswamy Sadineni, and Shiva Kumar Koppula, and Avanthi Basireddy, and Banothu Venkanna, and Shravan Kumar Gunda
October 2013, Mini reviews in medicinal chemistry,
Venkanna Gujja, and Kumaraswamy Sadineni, and Shiva Kumar Koppula, and Avanthi Basireddy, and Banothu Venkanna, and Shravan Kumar Gunda
October 2020, Bioorganic & medicinal chemistry letters,
Venkanna Gujja, and Kumaraswamy Sadineni, and Shiva Kumar Koppula, and Avanthi Basireddy, and Banothu Venkanna, and Shravan Kumar Gunda
December 2022, International journal of molecular sciences,
Venkanna Gujja, and Kumaraswamy Sadineni, and Shiva Kumar Koppula, and Avanthi Basireddy, and Banothu Venkanna, and Shravan Kumar Gunda
January 2023, ACS omega,
Venkanna Gujja, and Kumaraswamy Sadineni, and Shiva Kumar Koppula, and Avanthi Basireddy, and Banothu Venkanna, and Shravan Kumar Gunda
February 2012, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!